Skip to content
Baltimore News Journal – Lifestyle
Author:
Vima Therapeutics
Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson’s Disease
March 11, 2026